All Stories

Bristol Myers Squibb notches overall survival win with Opdivo in preoperative NSCLC

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a preoperative treatment for non-small cell lung cancer (NSCLC) as it has delivered an overall survival (OS) edge when added to chemotherapy.

Feb 19, 2025 - 21:32
 0
Bristol Myers Squibb notches overall survival win with Opdivo in preoperative NSCLC
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a preoperative treatment for non-small cell lung cancer (NSCLC) as it has delivered an overall survival (OS) edge when added to chemotherapy.
Read More

Tags:

Previous Article

Ionis marks 'milestone event' of Tryngolza launch with first campaigns targeting...

Next Article

Amazon to stop support for communications service Chime next year

Related Posts

With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors

With Teva competition heating up, Neurocrine's tame Ing...

Feb 10, 2025  0

Regulatory tracker: Bristol Myers snags dual cancer endorsements in EU

Regulatory tracker: Bristol Myers snags dual cancer end...

Feb 10, 2025  0

India’s Granules makes $22M play for Senn Chemicals to enter peptides CDMO business

India’s Granules makes $22M play for Senn Chemicals to ...

Feb 24, 2025  0